Manassas, VA, USA) and were cultured in endothelial cell medium containing Hyclone, Logan, UT, USA) and 100 U/ml penicillin and 100 µg/ml streptomycin 1 4 4 (Sangon, Shanghai, China) at 37°C in a humidified atmosphere of 5% CO 2 . (anti-miR-26a), inhibitor negative control (anti-miR-NC), pcDNA-GAS5 (GAS5), pcDNA empty control (pcDNA), siRNA against GAS5 (si-GAS5), siRNA 1 5 0 negative control (si-NC) (all from RiboBio Co., Ltd., Guangzhou, China) using Total RNA was extracted from clinical samples or treated HAECs using TRIzol miR-26a were examined using a SYBR Premix Ex Taq II (Takara, Dalian, expressions of GAS5 and miR-26a were normalized to GAPDH and U6 small Total proteins were extracted from the treated HAECs using RIPA buffer Technology, Danvers, MA, USA). After washing with TBST, the membranes were incubated with HRP-conjugated secondary antibody for 2 h at room
temperature. The protein bands were visualized using a chemiluminescence
kit (GE Healthcare, Buckinghamshire, UK) and protein intensity was quantified
with Image-Pro Plus 6.0 software (GE Healthcare). 
Flow cytometry analysis
Cell apoptosis was assessed using a FITC-Annexin V Apoptosis Detection Kit The wild-type fragment of GAS5 including the miR-26a binding sites and its
mutant sequence were subcloned into psiCHECK-2 luciferase reporter vector
(Promega, Madison, WI, USA) and named as GAS5-WT and GAS-MUT. For 100 nM miR-26a or miR-NC using Lipofectamine 2000 (Invitrogen), followed harvested and the luciferase activity was detected using the dual-Luciferase
Reporter Assay System (Promega). The relative luciferase activity was
normalized to the Renilla luciferase activity. MA, USA) was used to perform RIP assay was conducted using the. Briefly, RNA was subjected to qRT-PCR analysis. Briefly, biotinylated DNA probe complementary to GAS5 was amplified by PCR with a T7-containing primer and cloned into the plasmid vector GV394 (bio-miR-26a-MUT), and biotinylated NC (bio-NC) were synthesized by magnetic beads (Invitrogen). The bound RNAs were purified using TRIzol The data are presented as the mean ± standard deviation (SD). All statistical one-way analysis of variance (ANOVA). Differences were considered to be 2 3 6 statistically significant when P value < 0.05. The expressions of GAS5 and miR-26a in the plasma samples from 2 4 2 atherosclerotic patients and healthy controls were firstly detected by qRT-PCR.
GAS5 expression was upregulated and miR-26a was downregulated in

4 3
The results indicated that GAS5 expression was abnormally higher while with atherosclerosis compared with that from healthy controls (Fig. 1A and 1B ).
4 6
Next, we further analyzed the expressions of GAS5 and miR-26a in HAECs increased GAS5 expression and decreased miR-26a expression in HAECs
( Fig. 1C and 1D ). Collectively, these data suggested that abnormally To address the interaction between GAS5 and miR-26a, HAECs were transfected with GAS5, si-GAS5, miR-26a, anti-miR-26a, or respective 2 5 7 controls, followed by ox-LDL stimulation. We found that GAS5 expression was introduction in ox-LDL-treated HAECs ( Fig. 2A) . However, ox-LDL-treated
HAECs transfected with GAS5 showed a remarkable decline of miR-26a substantial enhancement of miR-26a expression (Fig. 2B) . Besides, miR-26a HAECs (Fig. 2C) . On the contrary, GAS5 expression was obviously lowered in
HAECs treated with miR-26a and ox-LDL but evidently augmented in HAECs 2 6 7 treated with anti-miR-26a and ox-LDL (Fig. 2D) . Together, these findings 2 6 8 uncovered that there was reciprocal inhibition between GAS5 and miR-26a
expressions in ox-LDL-treated HAECs. Based on the reciprocal repression between GAS5 and miR-26a expression,
we guessed whether the crosstalk between GAS5 and miR-26a is through predict the potential miRNAs for GAS5. As a result, the prediction showed the whether GAS5 could directly interact with miR-26a, we cloned the wild-type or 2 7 7 mutated fragment of GAS5 into psiCHECK-2 luciferase reporter vector and control IgG immunoprecipitates (Fig. 3C) . To confirm whether miR-26a could 2 8 8
directly interact with GAS5, we applied a biotin-labeled miRNA pull down to 2 8 9
